Cargando…

Vaccines for Canine Leishmaniasis

Leishmaniasis is the third most important vector-borne disease worldwide. Visceral leishmaniasis (VL) is a severe and frequently lethal protozoan disease of increasing incidence and severity due to infected human and dog migration, new geographical distribution of the insect due to global warming, c...

Descripción completa

Detalles Bibliográficos
Autor principal:	Palatnik-de-Sousa, Clarisa B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342354/ https://www.ncbi.nlm.nih.gov/pubmed/22566950 http://dx.doi.org/10.3389/fimmu.2012.00069

Ejemplares similares

Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines
por: Palatnik-de-Sousa, Clarisa Beatriz
Publicado: (2019)

The Delay in the Licensing of Protozoal Vaccines: A Comparative History
por: Palatnik-de-Sousa, Clarisa Beatriz, et al.
Publicado: (2020)

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
por: Borja-Cabrera, Gulnara Patricia, et al.
Publicado: (2004)

What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist
por: Palatnik-de-Sousa, Clarisa B.
Publicado: (2020)

One Health: The global challenge of epidemic and endemic leishmaniasis
por: Palatnik-de-Sousa, Clarisa B, et al.
Publicado: (2011)

Editorial: Epitope Discovery and Synthetic Vaccine Design
por: Palatnik-de-Sousa, Clarisa Beatriz, et al.
Publicado: (2018)

Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis
por: Barbosa Santos, Micheli Luize, et al.
Publicado: (2017)

Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis
por: Borja-Cabrera, GP, et al.
Publicado: (2009)

Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection
por: Nico, Dirlei, et al.
Publicado: (2014)

A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection
por: Alves-Silva, Marcus Vinícius, et al.
Publicado: (2017)

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune(®) vaccine
por: Santos, F.N., et al.
Publicado: (2007)

Immunogenicity assay of the Leishmune(®) vaccine against canine visceral leishmaniasis in Brazil
por: Borja-Cabrera, G.P., et al.
Publicado: (2008)

Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors
por: Nico, Dirlei, et al.
Publicado: (2012)

F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis
por: Carrillo, Eugenia, et al.
Publicado: (2017)

The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice
por: Alves-Silva, Marcus Vinícius, et al.
Publicado: (2019)

Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8(High) T Cells Are Associated With the Cure of Human Visceral Leishmaniasis
por: Rodrigues, Lorranny Santana, et al.
Publicado: (2021)

NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis
por: Nico, Dirlei, et al.
Publicado: (2018)

Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains
por: Nico, Dirlei, et al.
Publicado: (2014)

Vaccines for Canine Leishmaniasis
por: Foroughi-Parvar, Faeze, et al.
Publicado: (2014)

Peptide Vaccines for Leishmaniasis
por: De Brito, Rory C. F., et al.
Publicado: (2018)

A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden
por: Roatt, Bruno Mendes, et al.
Publicado: (2017)

Portrait of an ISV Fellow
por: Palatnik de Sousa, Clarisa Beatriz
Publicado: (2020)

A non-replicative antibiotic resistance-free DNA vaccine delivered by the intranasal route protects against canine leishmaniasis
por: Alonso, Ana, et al.
Publicado: (2023)

Cutaneous Leishmaniasis Vaccination: A Matter of Quality
por: De Luca, Paula Mello, et al.
Publicado: (2016)

Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis
por: Freitas, Elisangela Oliveira, et al.
Publicado: (2015)

Immunoprophylactic Potential of a New Recombinant Leishmania infantum Antigen for Canine Visceral Leishmaniasis: An In Vitro Finding
por: Pessoa-e-Silva, Rômulo, et al.
Publicado: (2021)

Protective Immunity and Vaccination Against Cutaneous Leishmaniasis
por: Okwor, Ifeoma, et al.
Publicado: (2012)

Canine Leishmaniasis, Italy
por: Ferroglio, Ezio, et al.
Publicado: (2005)

Canine Leishmaniasis in Bombay
por: Row, R.
Publicado: (1925)

Canine Leishmaniasis in Bombay
por: Avari, C. R., et al.
Publicado: (1924)

Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis
por: Saljoughian, Noushin, et al.
Publicado: (2014)

Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development
por: Volpedo, Greta, et al.
Publicado: (2021)

Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches
por: Joshi, Sumit, et al.
Publicado: (2014)

Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis
por: Moreno, Javier
Publicado: (2019)

Canine Leishmaniasis in an Endemic Area for Human Leishmaniasis in Nicaragua
por: Flores, Byron, et al.
Publicado: (2022)

A novel vaccine based on SARS-CoV-2 CD4(+) and CD8(+) T cell conserved epitopes from variants Alpha to Omicron
por: Palatnik-de-Sousa, Iam, et al.
Publicado: (2022)

Canine Leishmaniasis in Southeastern Spain
por: Martín-Sánchez, Joaquina, et al.
Publicado: (2009)

Redox Status in Canine Leishmaniasis
por: Quintavalla, Fausto, et al.
Publicado: (2021)

Dependency of B-1 Cells in the Maintenance of Splenic Interleukin-10 Producing Cells and Impairment of Macrophage Resistance in Visceral Leishmaniasis
por: Arcanjo, Angélica Fernandes, et al.
Publicado: (2017)

Challenges in the serological evaluation of dogs clinically suspect for canine leishmaniasis
por: Santarém, Nuno, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3mgflafp3mva8bq1ilq0ededc1